Human African trypanosomiasis: an emerging public health crisis

被引:0
|
作者
Smith, DH
Pepin, J
Stich, AHR
机构
[1] Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England
[2] Univ Sherbrooke, Fac Med, Sherbrooke, PQ, Canada
[3] Inst Wurzburg, Med Mission, Wurzburg, Germany
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is a dramatic resurgence of human African trypanosomiasis (HAT) in sub-Saharan Africa. T.b. gambiense is spreading epidemically in large areas of Central Africa, especially the Southern Sudan, Congo-Zaire, Angola, Uganda and the Central African Republic. Devastating epidemics of T.b. rhodesiense have occurred in south-eastern Uganda. The causes of the re-emergence of sleeping sickness as a public health problem include widespread civil disturbance and war, declining economies, reduced health financing and the dismantling of disease control programmes. Despite the inevitably fatal outcome without treatment, HAT is often given low priority by donors and national governments. The advances made in diagnosis, treatment and vector control have not been sufficiently implemented. To limit the human impact in some of the poorest communities in Africa, endemic countries will require external support to implement strategies for disease control. Donor agencies, NGOs and mission organisations could play an important role in supporting control efforts. National authorities will need to control and co-ordinate these efforts with assistance from WHO and the international community.
引用
收藏
页码:341 / 355
页数:15
相关论文
共 50 条
  • [41] CARDIAC VALVULITIS IN HUMAN AFRICAN TRYPANOSOMIASIS
    POLTERA, AA
    COX, JN
    OWOR, R
    EAST AFRICAN MEDICAL JOURNAL, 1977, 54 (09) : 497 - 499
  • [42] Current chemotherapy of human African trypanosomiasis
    Roberto Docampo
    Silvia N. Moreno
    Parasitology Research, 2003, 90 : S10 - S13
  • [43] AFRICAN HUMAN TRYPANOSOMIASIS - IMMUNOENZYMOLOGICAL DIAGNOSIS
    CAILLIEZ, M
    POUPIN, F
    SAVEL, J
    NOUVELLE PRESSE MEDICALE, 1979, 8 (07): : 522 - 523
  • [44] Drug resistance in human African trypanosomiasis
    Barrett, Michael P.
    Vincent, Isabel M.
    Burchmore, Richard J. S.
    Kazibwe, Anne J. N.
    Matovu, Enock
    FUTURE MICROBIOLOGY, 2011, 6 (09) : 1037 - 1047
  • [45] Current chemotherapy of human African trypanosomiasis
    Docampo, R
    Moreno, SNJ
    PARASITOLOGY RESEARCH, 2003, 90 (Suppl 1) : S10 - S13
  • [46] Eflornithine for the treatment of human African trypanosomiasis
    Burri, C
    Brun, R
    PARASITOLOGY RESEARCH, 2003, 90 (Suppl 1) : S49 - S52
  • [47] The epidemiology and control of human African trypanosomiasis
    Pépin, J
    Méda, HA
    ADVANCES IN PARASITOLOGY, VOL 49, 2001, 49 : 71 - 132
  • [48] Human African trypanosomiasis–neurological aspects
    P. G. E. Kennedy
    Journal of Neurology, 2006, 253 : 411 - 416
  • [49] IMMUNOLOGICAL DIAGNOSIS OF HUMAN AFRICAN TRYPANOSOMIASIS
    SAVEL, J
    COULAUD, JP
    MEDECINE ET MALADIES INFECTIEUSES, 1979, 9 (05): : 293 - 295
  • [50] The human African trypanosomiasis (HAT) platform
    Mbo, F.
    Valverde, O.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 : 239 - 239